Publish in this journal
Journal Information
Visits
Not available
Vol. 68. Issue 7.
Pages 599-611 (July 2015)
Review article
DOI: 10.1016/j.rec.2015.02.025
Full text access
Adipose-derived Mesenchymal Stem Cells and Their Reparative Potential in Ischemic Heart Disease
Células madre mesenquimales derivadas de tejido adiposo y su potencial reparador en la enfermedad isquémica coronaria
Visits
...
Lina Badimona,b,
Corresponding author
lbadimon@csic-iccc.org

Corresponding author: Centro de Investigación Cardiovascular, Sant Antoni M. Claret 167, 08025 Barcelona, Spain.
, Blanca Oñatea, Gemma Vilahura
a Centro de Investigación Cardiovascular, CSIC-ICCC, Hospital de la Santa Creu i Sant Pau e IIB-Sant Pau, Barcelona, Spain
b Cátedra de Investigación Cardiovascular, UAB-HSCSP-Fundación Jesús Serra, Barcelona, Spain
This item has received
...
Visits
(Daily data update)
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (5)
Table 1. Factors Secreted by Adipose Tissue
Table 2. Characteristic Cell Surface Markers of Adipose-derived Stem Cells
Table 3. Experimental Studies Using Rodent and Rabbit Animal Models
Table 4. Preclinical Studies with Porcine Models
Table 5. Clinical Trials Performed with Adipose-derived Stem Cells
Show moreShow less
Abstract

Adipose tissue has long been considered an energy storage and endocrine organ; however, in recent decades, this tissue has also been considered an abundant source of mesenchymal cells. Adipose-derived stem cells are easily obtained, show a strong capacity for ex vivo expansion and differentiation to other cell types, release a large variety of angiogenic factors, and have immunomodulatory properties. Thus, adipose tissue is currently the focus of considerable interest in the field of regenerative medicine. In the context of coronary heart disease, numerous experimental studies have supported the safety and efficacy of adipose-derived stem cells in the setting of myocardial infarction. These results have encouraged the clinical use of these stem cells, possibly prematurely. Indeed, the presence of cardiovascular risk factors, such as hypertension, coronary disease, diabetes mellitus, and obesity, alter and reduce the functionality of adipose-derived stem cells, putting in doubt the efficacy of their autologous implantation. In the present article, white adipose tissue is described, the stem cells found in this tissue are characterized, and the use of these cells is discussed according to the preclinical and clinical trials performed so far.

Keywords:
Adipose tissue
Adipose-derived stem cells
Regenerative medicine
Ischemic heart disease
Cardiovascular risk factors
Abbreviations:
ADSCs
MSCs
SVF
WAT
Resumen

Se ha considerado al tejido adiposo como de almacenamiento energético y como un órgano endocrino; sin embargo, en las últimas décadas se lo ha considerado como una fuente abundante de células mesenquimales. Las células madre derivadas del tejido adiposo son de fácil obtención, presentan una gran capacidad de expansión ex vivo y gran plasticidad a otros tipos celulares, liberan gran variedad de factores angiogénicos y presentan propiedades inmunomoduladoras. Por ello, actualmente constituyen un foco de gran interés en la medicina regenerativa. En el contexto de enfermedad cardiaca coronaria, múltiples estudios experimentales han avalado la seguridad y la eficacia del uso de las células madre derivadas del tejido adiposo en el contexto de infarto de miocardio. Todo ello ha promovido, quizá precozmente, su uso clínico. De hecho, se ha demostrado que la presencia de factores de riesgo cardiovascular como hipertensión, enfermedad coronaria, diabetes mellitus u obesidad, altera y merma la funcionalidad de las células madre derivadas del tejido adiposo, lo que deja en entredicho la eficacia basada en el implante de células madre derivadas del tejido adiposo autólogas. En el siguiente artículo se describe el tejido adiposo blanco, se caracterizan las células madre que lo componen y se discute sobre su uso según los estudios preclínicos y clínicos realizados hasta el momento.

Palabras clave:
Tejido adiposo
Células madre derivadas del tejido adiposo
Medicina regenerativa
Enfermedad isquémica coronaria
Factores de riesgo cardiovascular
Full Text
ADIPOSE TISSUE

Adipose tissue is one of the most abundant human tissues. It constitutes between 15% and 20% of the body weight of men and between 20% to 25% of that of women and is widely distributed throughout various body regions. This specialized tissue is of mesenchymal origin, consisting of a combination of white adipose tissue (WAT) and brown adipose tissue, with each tissue type showing distinct functions, morphologies, and distributions. In both tissues, the predominant cell is the adipocyte, comprising between one- and two-thirds of the total, and the remaining tissue is composed of different types of cells constituting the stromal vascular fraction (SVF).

White Adipose Tissue

Although WAT is distributed throughout the body, its principal deposits are subcutaneous, where it acts as an energy storage system, and in the visceral or intra-abdominal region, where it protects against possible trauma. The 2 tissues show different adipokine expression profiles,1 metabolic functions,2 vascular density, and innervation. Visceral adipose tissue shows a higher angiogenic potential and more acute inflammatory profile than subcutaneous tissue.3 The accumulation of subcutaneous adipose tissue represents a physiological response to situations of excessive intake and low energy expenditure (physical inactivity), acting as an “energy sink”. Individuals with peripheral obesity (subcutaneous distribution) do not show the characteristic medical complications of obesity. In contrast, increased visceral adipose tissue (central obesity) is associated with a state of hyperglycemia, hyperinsulinemia, hypertriglyceridemia, hypercholesterolemia, reduced circulating levels of high-density lipoproteins, decreased glucose tolerance, increased apolipoprotein B-rich lipoproteins, and hepatic steatosis. All of these conditions are characteristics of insulin resistance syndrome, which increases the risk of the development of type 2 diabetes mellitus.4 Currently, waist size is an important diagnostic component of metabolic syndrome and has been identified as an independent risk factor for other diseases, such as cardiovascular diseases, stroke, hypertension, and nonalcoholic fatty liver disease.5–7

The main function of WAT is to regulate the energy homeostasis of the body, which is under the control of the nervous and endocrine systems. In times of caloric excess, adipose tissue stores fat in the form of triglycerides. These lipids are then released into the blood in times of energy demand to be used as an energy source in other tissues, such as the liver, kidneys, skeletal muscle, and myocardium.8 However, WAT is currently considered a multifunctional organ because, besides its energy function, it acts as an endocrine organ and as a reservoir of mesenchymal stem cells (MSCs).

Composition of White Adipose Tissue

White adipose tissue consists of mature adipocytes and intercellular tissue or SVF. Adipocytes, the most abundant cells in adipose tissue, contain a single large cytoplasmic vacuole that mainly stores triglycerides and cholesterol esters. Depending on nutritional status, adipocytes can alter their size to between 25 μm and 200μm. Adipocytes contain the machinery necessary for lipid metabolism (Figure 1).9 These pathways can be altered by an increase in weight, triggering insulin resistance syndrome. Indeed, fatty acids not only show an energy function, but also act as regulatory signals of the gene expression of proteins involved in lipid metabolism,10 favor a prothrombotic state, and are associated with inflammatory processes.11 Thus, an excess of circulating fatty acids (lipotoxicity) is one of the strongest links between obesity and the development of metabolic syndrome and/or cardiovascular disease. When calorie consumption exceeds energy expenditure, a metabolic state develops that promotes adipocyte hypertrophy (increased size) and hyperplasia (increased number).12 The latter involves mobilization of stem cells toward the adipocyte lineage (adipogenesis). New or small adipocytes are more sensitive to insulin and show a marked capacity for the uptake of free fatty acids and triglycerides in the postprandial period.4 As adipocytes increase in size (hypertrophy), they become dysfunctional, losing their ability to protect against systemic lipotoxicity, and ectopic fat begins to accumulate. These distended adipocytes become hyperlipolytic and resistant to insulin and its antilipolytic signals. Another important function performed by adipocytes is that of endocrines cells, as discussed below.

Figure 1.

Diagram illustrating the lipogenesis and lipolysis processes occurring in mature adipocytes. After eating and an increase in blood insulin, lipogenesis is activated in adipocytes. In this process, adipocytes, via lipoprotein lipase, degrade the triglycerides of chylomicrons and of very-low-density lipoprotein to fatty acids. These molecules enter the adipocyte to be esterified with glycerol-3 phosphate and synthesize the triglycerides that are stored in the lipid vacuole. In the adipocyte, insulin not only stimulates lipoprotein lipase synthesis, but also stimulates uptake and metabolism of glucose to glycerol-3 phosphate. In contrast, during lipolysis, the triglycerides stored are mobilized to produce free fatty acids and glycerol to meet the energy requirements of the body. Catabolic hormones, secreted in response to a low blood concentration of glucose, activate the synthesis and movement of hormone-sensitive lipase from the cytosol to the surface of the lipid vacuole, where hormone-sensitive lipase hydrolyzes triglycerides. The fatty acids produced are secreted as free fatty acids to the circulation, where they will be transported by albumin to the target organs to be oxidized to produce energy. Similarly, the glycerol derived from lipolysis is also released into the circulation to be used by the liver as a source of carbon. AQP7, aquaporin-7; CM, chylomicrons; FABP, fatty acid-binding protein; FAT/CD36, fatty acid translocase; FATP, fatty acid transport protein; GLUT4, glucose transporter type 4; HSL, hormone-sensitive lipase; LPL, lipoprotein lipase; TG, triglycerides; VLDL, very-low-density lipoprotein.

(0.32MB).

The other component of WAT is the SVF. Although the cells constituting the SVF remain to be fully defined, they include adipocyte precursors and vascular and blood cells.13 Pericytes form the vasculature of adipose tissue, together with endothelial and smooth muscle cells. The extent and characteristics of this capillary network are crucial for processes such as the growth, function, and development of adipose tissue.14 Adipocytes and other cells of the SVF secrete proangiogenic factors, ensuring that the tissue has a generous blood supply. In addition, adipose tissue, via its resident immune system cells, strongly controls the metabolism of the body. In nonobese individuals, these cells are involved in elimination of necrotic adipocytes, remodeling of the extracellular matrix, angiogenesis, adipogenesis, and maintaining insulin sensitivity. However, in obese individuals, the number of immune system cells increases; these cells acquire a proinflammatory phenotype and release a huge number of cytokines in charge of recruiting and activating other immune system cells and inducing insulin resistance syndrome in adipose tissue.15 Macrophages are the cells with the most important role in the acquisition of the low-grade chronic proinflammatory state that characterizes obesity. During adipose tissue expansion, there is a greater recruitment of M1 macrophages (a proinflammatory phenotype). These macrophages secrete most of the proinflammatory cytokines found in obese adipose tissue,16 whereas the resident M2 macrophages show an anti-inflammatory phenotype.17 Finally, in the SVF, there are adipose-derived stem cells (ADSCs) and preadipocytes. These cell populations are in charge of maintaining adipocyte population renewal in physiological conditions and play a vital role in the obesity-related expansion of adipose tissue. The differences between these 2 cell groups are poorly defined. Both ADSCs and preadipocytes show a similar morphology. However, whereas ADSCs can differentiate into other lineages and show a large capacity for self-renewal, preadipocytes have lost these differentiation capabilities and can only generate mature adipocytes.18

Factors Secreted by White Adipose Tissue

The WAT secretes a multitude of bioactive peptides, known under the umbrella term of adipocytokines or adipokines (Table 1).19,20 However, many of these factors are not only secreted by adipocytes, but also by the cells constituting the SVF, such as macrophages and ADSCs. Through these secreted factors, adipose tissue participates in the autocrine and paracrine regulation of adipose tissue itself, as well as affecting the function of other organs. In addition, adipose tissue is in charge of regulating energy homeostasis and body weight, insulin sensitivity, and various functions of the immune, vascular, and reproductive systems.20 This endocrine function of adipose tissue explains the pathophysiological relationship between excess body fat and its associated pathological states, because obesity and/or metabolic syndrome trigger a dysregulation of the secreted amounts of these molecules.21

Table 1.

Factors Secreted by Adipose Tissue

Adipokines  Function  Secreting cell  Regulation 
11β-hydroxysteroid dehydrogenase type 1  Steroid metabolism  Adipocytes, preadipocytes  ↑ obesity 
Free fatty acids  Lipid metabolism  Adipocytes  ↑ obesity 
Adiponectin  Increases insulin sensitivity, inflammation, and arteriosclerosis  Adipocytes  ↓ obesity 
Adipsin and acylation stimulating protein (ASP)  Stress and immune response  Adipocytes, M2 macrophages  ↑ obesity 
Angiotensinogen  Vascular homeostasis  Adipocytes, SVF  ↑ obesity 
Apelin  IR  Adipocytes, SVF, macrophages  ↑ obesity 
Aromatase  Lipid metabolism  Adipocytes, ADSCs, macrophages  ↑ obesity 
IGF-1  Lipid metabolism and IR  Adipocytes, preadipocytes, ADSCs   
TNFα  Inflammation, arteriosclerosis, and IR  Adipocytes, M1 macrophages  ↑ obesity 
Macrophage migration inhibitory factor (MIF)  Inflammation  Adipocytes, ADSCs, immune system cells  ↑ obesity 
TGFβ  Cell adhesion and migration, growth and differentiation  Adipocytes, SVF, ADSCs  ↑ obesity 
Steroid hormones  Lipid metabolism and IR  Adipocytes, preadipocytes  ↑ obesity 
PAI-1  Vascular homeostasis  Adipocytes, SVF  ↑ obesity 
IL-1  Inflammation and IR  M1 macrophages  ↑ obesity 
IL-6  Inflammation, arteriosclerosis, and IR  Adipocytes, SVF  ↑ obesity 
IL-8  Pro-atherogenesis  Adipocytes, SVF  ↑ obesity 
IL-10  Inflammation and IR  Adipocytes, M2 macrophages  ↑ obesity, ↓ MS 
Leptin  Dietary intake, reproduction, angiogenesis, and immune system  Adipocytes  ↑ obesity 
Hormone-sensitive lipase  Lipid metabolism  Adipocytes  ↓ obesity 
Lipoprotein lipase  Lipid metabolism  Adipocytes  ↑ obesity 
Metallothionein  Stress and immune response  Adipocytes, SVF  ↑ obesity 
Monobutyrin  Angiogenesis  Adipocytes  ↑ obesity 
Omentin  IR  SVF, macrophages  ↓ obesity 
Perilipin  Lipid metabolism  Adipocytes  ↑ obesity 
Prostaglandins (PGE2, prostacyclin, PG2Fα)  Blood flow, lipolysis, cellular differentiation  Adipocytes, ADSCs  ↑ obesity 
C-reactive protein  Inflammation, arteriosclerosis, and IR  SVF  ↑ obesity 
Fatty acid-binding protein (FABP4/aP2)  Lipid metabolism  Adipocytes, macrophages  ↑ obesity 
MCP-1  Pro-atherogenesis and IR  Adipocytes, M1 macrophages  ↑ obesity 
CETP  Lipid metabolism  Preadipocytes, adipocytes  ↑ obesity 
RBP  Lipid metabolism  Adipocytes  Variable in obesity 
Resistin  Inflammation and IR  Adipocytes, M2 macrophages  Variable in obesity 
Thrombospondin  Angiogenesis  Adipocytes  ↑ obesity 
Visfatin  IR  Adipocytes, preadipocytes, neutrophils  Variable in obesity 
Zinc-α2-glycoprotein  Lipid metabolism, cancer, and cachexia  Adipocytes, SVF  ↓ obesity 

ADSCs, adipose-derived stem cells; CETP, cholesteryl ester transfer protein; IGF-1, insulin-like growth factor 1; IR, insulin resistance; IL, interleukin; MCP-1, monocyte chemoattractant protein-1; MS, metabolic syndrome; RBP, retinol-binding protein; PAI-I, plasminogen activator inhibitor-1; SVF, stromal vascular fraction; TGFβ, transforming growth factor beta; TNFα, tumor necrosis factor alpha.

Adapted from Ronti et al.20

ADIPOSE-DERIVED STEM CELLS

For many years, the hyperplastic growth of adipose tissue was believed to be due to the existence of a unipotent progenitor cell population, the preadipocytes. However, in 2001, Zuk et al22 identified the existence of MSCs with self-renewal and multipotent capacities in adipose tissue. Since then, adipose tissue has been considered a source of MSCs for use in cell therapy.22

Origin of Adipose-derived Stem Cells

Since adipocytes and their progenitors were found to originate from MSCs,23 it has been noted that ADSCs could be derived from mesenchymal lineage cells from the bone marrow. Indeed, the cells of the SVF show various similarities with those of the bone marrow. Both stromae contain a heterogeneous population of MSCs with the ability to differentiate into various lineages (adipocytic, chondrocytic, and myogenic) according to culture conditions.24 Mansilla et al25 noted that the bone marrow is the principal producer of the MSCs that supply the populations of MSCs found in other peripheral organs (peripheral reservoirs). Additionally, these authors showed that the cells are maintained in a quiescent and undifferentiated state until they are “called” to proliferate and move to the required tissues. Indeed, although there are practically no MSCs in the circulation of healthy individuals, these stem cells are mobilized toward damaged regions to participate in tissue repair and regeneration.26 Thus, it can be inferred that obese adipose tissue, as an important source of chemotactic factors, would act as a niche where circulating MSCs could home to and differentiate into adipocytes.25

Characteristics of Adipose-derived Stem Cells

Adipose-derived stem cells show the typical characteristics of MSCs proposed by the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy:27

  • They must adhere to plastic while maintained in standard culture conditions.

  • They must be able to differentiate into osteogenic, adipogenic, and chondrogenic lineages (Figure 2).

    Figure 2.

    Adipose-derived stem cells differentiation potential. Adipose-derived stem cells are able to differentiate to other types of cells of the same mesodermal lineage (transdifferentiation) or to other types of cells from another lineage (cross-differentiation). ADSCs, adipose-derived stem cells; FABP4, fatty acid-binding protein 4; GFAP, glial fibrillary acidic protein; Ipf-1, insulin promoter factor 1; Isl-1, islet 1; LDL, low-density lipoprotein; LPL, lipoprotein lipase; MAP-2, microtubule-associated protein 2; MyoD1, myogenic differentiation factor 1; NeuN, neuronal nuclear antigen; Ngn-3, neurogenin 3; Nkx2.5, NK2 homeobox 5; OCN, osteocalcin; OPN, osteopontin; Pax-6, paired box protein 6; PECAM-1, platelet endothelial cell adhesion molecule 1; RUNX2, runt-related transcription factor 2; Tie-2, angiopoietin receptor 2; VE, vascular endothelial; VEGFR2, vascular endothelial growth factor 2; vWF, von Willebrand factor.

    (0.37MB).
  • They must express the surface markers CD105, CD73, and CD90 and not express CD45, CD34, CD14 or CD11b, CD79a, or CD19, or HLA-II surface molecules.

Although ADSCs do not express a single surface marker that enables their identification, they express the characteristic markers of MSCs in conjunction with some markers expressed by nonprogenitor lines (Table 2).

Table 2.

Characteristic Cell Surface Markers of Adipose-derived Stem Cells

Markers found in ADSCsMarkers not found in ADSCs
αSMA  α-Smooth muscle actin (ACTA2)  CD104a  β4 integrin 
CD10  Neutral endopeptidase (NEP)  CD106a  Component of vascular cell adhesion molecule-1 (VCAM-1) 
CD105  Endoglin (SH2)  CD117  c-Kit 
CD13  Alanine aminopeptidase  CD11b  αM integrin 
CD146  Melanoma cell adhesion molecule (MCAM)  CD11c  αX integrin 
CD166  Activated leukocyte cell adhesion molecule (ALCAM)  CD133  Prominin 1 
CD24  Heat-stable antigen (HSA)  CD14   
CD29  β1 integrin  CD144  VE-cadherin 
CD44  Hyaluronic acid/fibronectin receptor  CD15  Stage-specific embryonic antigen-1 (SSEA-1) 
CD49da  α4 integrin  CD16  Fc receptor for IgG 
CD49e  α5 integrin  CD19  B lymphocyte surface antigen B4 
CD54a  Intracellular adhesion molecule-1 (ICAM-1)  CD3  T cell receptor (TCR) 
CD55  Complement decay-accelerating factor (DAF)  CD31  Platelet endothelial cell adhesion molecule 1 (PECAM-1) 
CD58    CD33   
CD59  Membrane attack complex inhibition factor (MACIF)  CD34b   
CD71  Transferrin receptor  CD38   
CD73  Ecto-5’-nucleotidase (SH3)  CD4  MHC-II coreceptor 
CD9    CD45  Leukocyte common antigen (LCA) 
CD90  Thymus cell antigen-1 (Thy-1)  CD56  Neural cell adhesion molecule (NCAM) 
HLA-I  Human leukocyte antigen class I (A, B, C)  CD61  β3 integrin 
Sca-1  Stem cell antigen 1, ly-6A/E  CD62E  E-selectin 
    CD62P  P-selectin 
    CD79a  Immunoglobulin-associated α 
    CD80  B7.1 
    Gly-A  Glycophorin A 
    HLA-DR  Human leukocyte antigen class II (DR, DP, DQ) 
    Linc  Lineage antigen 
    MyD88  Myeloid differentiation primary response gene (88) 
    Stro-1a  Stromal cell antigen-1 (at low levels) 
    VEGFR2  Vascular endothelial growth factor receptor 2 (Flk-1, KDR) 

ADSCs, adipose-derived stem cells; BM-MSCs, bone marrow-derived mesenchymal stem cells.

a

Marker that is oppositely expressed between adipose-derived stem cells and bone marrow-derived mesenchymal stem cells.

b

Marker with controversial ADSC expression results; some authors detect it, whereas others do not.

c

Lin antigens consist of the following group of lineage markers: CD2, CD3, CD4, CD5, CD8, NK1.1, B220, Ter-119, and Gr-1 (granulocyte differentiation antigen 1).

As metabolically active cells, ADSCs play important roles in the revascularization of damaged tissue, apoptosis inhibition, and immunomodulation. These stem cells secrete a large quantity of extracellular matrix factors and a large number of cytokines and growth, angiogenic, and antiapoptotic factors.28 Indeed, a large part of the beneficial effects of cell therapy with ADSCs is believed to be due to their robust secretion of paracrine factors. Importantly, these angiogenic and antiapoptotic factors are secreted in bioactive quantities, and this secretion is increased under hypoxia.29

Source-related Differences in Adipose-derived Stem Cells

The metabolic differences between subcutaneous and visceral adipose tissue may be due to the intrinsic characteristics of the cells resident in each tissue, including ADSCs. Indeed, adipocytes differentiated in vitro from ADSCs derived from the 2 sources show differences inherent to the source tissues.30 These differences are stable and are maintained after the ADSCs have been isolated and cultured in vitro.31 Various studies have reported differences in the proliferation, differentiation, and apoptotic potentials, as well as gene expression patterns, of ADSCs from different adipose tissues.32–34 Adipose-derived stem cells from subcutaneous adipose tissue show greater adipogenic differentiation capacity than ADSCs from visceral adipose tissue.32 The low capacity for differentiation of the visceral ADSCs could partly explain why fat accumulates in already existing adipocytes and, consequently, why the size of their lipid vacuoles increases. In contrast, the greater differentiation capacity of subcutaneous ADSCs would result in lipid accumulation in new adipocytes with smaller vacuoles.35 Accordingly, the size of the lipid vacuoles of visceral adipocytes correlates with the concentrations of circulating lipids, whereas the degree of hyperplasia and size of the subcutaneous adipocytes are more related to the plasma concentrations of glucose and insulin and to insulin sensitivity.36 However, it is still unknown how the ADSCs of each adipose tissue acquire their characteristic phenotypes and at what developmental stage. The regional characteristics of the different ADSCs might be regulated epigenetically, appearing during early developmental phases and being established later by the environment of each adipose tissue and of each individual. Knowledge of the differences between the ADSCs of the different adipose tissues would be of great interest for a better understanding of the biology of the tissue and the development of its different deposits.

Effect of Cardiovascular Risk Factors on Adipose-derived Stem Cells

Various studies have shown that hypercholesterolemia, types 1 and 2 diabetes mellitus, hypertension, and smoking negatively affect endogenous stem/progenitor cells. Recently, our group has reported that type 2 diabetes mellitus negatively affects the pluripotency and self-renewal capacities of ADSCs, altering the main pathways involved in the maintenance of stem cells and their differentiation and angiogenic potentials.37

Obesity has also been described as a disease that affects ADSCs. Van Harmelen et al38 found that the adipogenic differentiation capacity of ADSCs of subcutaneous mammary adipose tissue is decreased in women with a high body mass index. Subsequently, Nair et al39 reported that ADSCs from subcutaneous adipose tissue of obese Pima Indian individuals had higher expression of proinflammatory genes than those of nonobese individuals. Recently, it has been reported that morbidly obese individuals have ADSCs with impaired proliferation, differentiation, and angiogenic capacities, which negatively affect the regenerative capacity of these cells.40 Additionally, the ADSCs of obese patients show lower levels of multipotency markers, increased commitment toward an adipocyte lineage, and higher expression of proinflammatory genes than ADSCs derived from nonobese patients.41 In addition, the effect of obesity on ADSCs was seen in both those cells derived from subcutaneous adipose tissue and those derived from visceral tissue.42

ADIPOSE-DERIVED STEM CELLS IN CELL THERAPY

Bone marrow-derived MSCs have been used for many years as the main source of stem cells for regenerative medicine and as an alternative to embryonic stem cells.43 However, due to the ease of acquisition and isolation of ADSCs and the large quantity obtained, they have become an important alternative source of stem cells with considerable advantages over bone marrow-derived MSCs.44,45 Initially, the reparative/regenerative capacity of ADSCs was proposed to be due to their ability to differentiate into other cell types.46 However, studies performed in recent years have confirmed that the reparative potential of ADSCs is largely due to their release of paracrine factors.44,45

Adipose-derived Stem Cells in Ischemic Heart DiseaseExperimental Studies

In recent years, numerous preclinical studies and some clinical studies have analyzed the safety, behavior, and efficacy of ADSCs in the treatment of ischemic injury, especially that of cardiac origin.47–51 The first study was performed in a rat model of heart cryoinjury and involved the injection of recently isolated ADSCs into the left ventricular cavity to simulate intracoronary administration.51 That study was the first to show that ADSCs home to the myocardium and express specific markers of cardiac cells. Similarly, functional and pathological analyses of the ADSC-treated animals revealed significantly improved global cardiac function and increased capillary density in the injury border zone compared with controls.51 Since then, the capacity of ADSCs to generate cardiomyocytes and vascular cells has become a topic of great experimental interest, as shown in Table 351-91 (studies performed in rodents and rabbits) and Table 492–101 (studies performed in porcine models). Notably, controversy surrounds the efficacy of the ADSCs. Whereas some studies have found engrafted ADSCs expressing specific cardiac markers (troponin I and myosin light chain),51,102–105 von Willebrand factor, and/or smooth muscle actin, other studies failed to discern the differentiation capacity of ADSCs (Tables 3 and 4).52,92 These differences in the in vivo differentiation potential of ADSCs could be due to differences in ADSC sources, procurement processes or culture media, animal models, or means of administration, or be due to the limits of histological analysis. Various groups have similarly found a low differentiation capacity of ADSCs in studies in vivo.52,53,92 All of these observations have led scientists to question whether the benefits derived from ADSC administration are directly related to the differentiation processes or if, in contrast, they are conditioned by ADSC secretion of paracrine factors.106–108

Table 3.

Experimental Studies Using Rodent and Rabbit Animal Models

Authors  Cell source  Animal model  Lesion  Result 
Strem et al51  ADSCs from mouse subcutaneous adipose tissue  Mouse  AMI induced by cryolesion  The implanted ADSCs expressed specific markers of cardiomyocytes 
Miyahara et al55  Sheets of ADSCs from rat subcutaneous adipose tissue  Rat  AMI induced by LAD ligation  Improved injury and cardiac function 
Zhang et al56  Rabbit ADSCs  New Zealand white rabbit  AMI induced by LAD ligation  Improved cardiac function 
Mazo et al57  ADSCs from subcutaneous adipose tissue, AD-CMGs, and BM-MNCs from GFP-mice  SD rat  AMI induced by LAD ligation  ADSCs improved cardiac function and tissue viability, increased angiogenesis, and reduced fibrosis 
Cai et al52  ADSCs from human subcutaneous adipose tissue  Rat  AMI induced by LAD ligation  ADSCs improved cardiac function and tissue viability, increased angiogenesis, and reduced fibrosis 
Léobon et al58  AD-CMGs from subcutaneous adipose tissue  Mouse  AMI followed by AD-CMG injection  After 4 weeks, the group treated with AD-CMGs showed reduced remodeling and LVEF stability and increased angiogenesis in the peri-infarct zones 
Schenke-Layland et al59  ADSCs from rat subcutaneous adipose tissue  Rat  AMI induced by LAD occlusion and reperfusion  Improved cardiac function despite few implanted cells 
Van der Bogt et al60  ADSCs from mouse subcutaneous adipose tissue and BM-MSCs  Transgenic FVB mouse  AMI  No improvement detected. Increased apoptosis 
Wang et al61  ADSCs from rat subcutaneous adipose tissue  Rat  AMI induced by LAD occlusion  After 1 month, improved LVEF, thickening of the cardiac wall, and increased capillary density. Only 0.5% of the ADSCs implanted were positive for specific cardiac cell markers 
Zhu et al62  ADSCs from human subcutaneous adipose tissue overexpressing HGF  SD rat  AMI  ADSCs improved cardiac function and reduced fibrosis 
Bai et al53  ADSCs from human subcutaneous adipose tissue  SCID mouse  AMI  Improved cardiac function, cardiomyogenic differentiation, and increased angiogenesis 
Bayes-Genis et al63  ADSCs from human cardiac adipose tissue  Mouse and rat  AMI  Improved cardiac function, cardiomyogenic differentiation, and increased vasculogenesis 
Danoviz et al64  ADSCs from rat subcutaneous adipose tissue. Injected with fibrin α, collagen, or culture medium  Rat  AMI  Inhibition of the negative process of cardiac remodeling 
Hwangbo et al65  Human ADSCs  SD rat  AMI induced by permanent ligation of the LAD  After 4 weeks, improved cardiac function and cardiomyogenic differentiation and increased capillary density 
Lin et al66  ADSCs from epididymal adipose tissue of rat treated with sildenafil  Lewis rat  Dilated cardiomyopathy  Less apoptosis and fibrosis, improved cardiac function, and increased angiogenesis 
Okura et al67  ADSCs from human omental adipose tissue differentiated to cardiomyocytes  Nude rat  AMI  Improved cardiac function and increased cardiomyogenic differentiation 
Zhang et al68  ADSCs from the subcutaneous adipose tissue of rats co-injected with fibrin  Rat  AMI  ADSCs + fibrin improved cell implantation, tissue injury, cardiac function, and vascular density 
Bai et al69  ADSCs from human subcutaneous adipose tissue  Nude mouse  AMI induced by permanent ligation of the LAD  Implantation of ADSCs; 3.5% of the cells differentiated to cardiomyocytes or endothelial cells 
Berardi et al70  Human ADSCs treated with SNAP  Rat  AMI  ADSCs treated with SNAP had improved cardiac function and increased expression of troponin T and von Willebrand factor 
Cai et al71  ADSCs from rat subcutaneous adipose tissue co-cultured with cardiomyocytes  Rat  AMI  Pretreatment of ADSCs improved their implantation and capacity for repair of cardiac function 
Gaebel et al72  Human ADSCs, BM-MSCs, and MSCs from umbilical cord blood  SCID mouse  LAD ligation  Human MSCs derived from different tissues showed differences in their capacity for repair of cardiac function. CD105+ cells showed better survival in infarcted hearts 
Hamdi et al73  ADSCs from rat subcutaneous adipose tissue in the form of sheets  Rat  Coronary ligation  Rats treated with ADSC sheets survived longer than those that received cell injections. Reduced remodeling of the left ventricle and improved final diastolic volume and cell transplantation 
Ii et al54  Human ADSCs  Nude rat  AMI  Improved cardiac function, increased capillary density, no transdifferentiation to cardiac or vascular lineages 
Van Dijk et al74  SVF cells and ADSCs from rat subcutaneous adipose tissue  Rat  AMI  SVFs and ADSCs significantly decreased infarct size when they were injected 7 days after the infarct, not the first day 
Bagno et al75  ADSCs from rat subcutaneous adipose tissue + matrigel  Wistar rat    After 6 weeks, improved cardiac function and decreased scarring 
Beitnes et al76  ADSCs from human subcutaneous adipose tissue and MSCs from human skeletal muscle  Nude rat  AMI  Improved cardiac function and decreased scar size 
Fang et al77  Amniotic epithelial cells, MSCs from umbilical cord, and ADSCs from human subcutaneous adipose tissue  Athymic nude rat  AMI  Improved cardiac function and decreased scar size 
Hoke et al78  ADSCs from human epicardiac adipose tissue treated with phosphodiesterase-5 inhibitor  CD-1 mouse  AMI  Improved cardiac function, increased vascular density, reduced apoptosis, increased secretion of VEGF, FGF-b, and Ang1 
Li et al79  Human CDCs, BM-MSCs, ADSCs, and BM-MNCs  Mouse  AMI  After 3 weeks, improved cardiac function, increased engraftment and myogenic lineage differentiation 
Liu et al80  ADSCs from rat subcutaneous adipose tissue in chitosan hydrogel  SD rat  AMI induced by LAD ligation  Increased stem cell engraftment, survival, and homing 
Paul et al81  Human ADSCs injected in genipin cross-linked alginate chitosan microcapsules  Lewis rat  AMI induced by LAD occlusion  Improved retention of implanted cells, decreased infarct zone size, increased vasculogenesis, and improved cardiac function 
Paul et al82  Human ADSCs overexpressing Ang-1  Rat  AMI  Increased cell retention and capillary density, decreased infarct zone, and increased cardiac function 
Shi et al83  ADSCs from rat subcutaneous adipose tissue overexpressing eNOS  Rat  AMI  Decreased infarct zone size 
Yang et al84  HO-1-ADSCs from rabbit subcutaneous adipose tissue  Rabbit  AMI  Improved cardiac function, left ventricular size, and cardiomyogenic and angiogenic differentiation 
Paul et al85  Human ADSCs and BM-MSCs  Rat  AMI  Improved cardiac function 
Wang et al86  Human ADSCs with/without shPHD2 silencing  Mouse  AMI  ADSCs decreased cardiomyocyte apoptosis, fibrosis, and infarct zone size and improved cardiac function. shPHD2-ADSCs further increased these improvements and induced better ADSCs survival. Conditioned medium from the shPHD2-ADSCs decreased cardiomyocyte apoptosis and increased IGF-1 
Godier-Furnémont et al87  Patches containing TGFß-1–conditioned human MSCs  Nude rat  LAD occlusion  Decreased myocyte apoptosis 
Karpov et al88  BM-MSCs and ADSCs injected 7 days after infarction  Rat  LAD occlusion and reperfusion  Animals transplanted with BM-MSCs preserved better left ventricular function and had decreased scar size 
Jiang et al89  MSCs  Rat  LAD ligation and remote ischemic postconditioning  Remote ischemic postconditioning increased the SDF-1a concentration and increased the injected MSC retention 
Hong et al90  ADSCs, EPCs, ADSCs + EPCs  Rat  LAD ligation  Increased LVEF and increased angiogenesis in the peri-infarct zone in the 3 groups 
Sun et al91  ADSCs embedded in a platelet-rich fibrin scaffold  Rat  AMI induced by LAD occlusion  Improved function and vascular remodeling with ADSCs embedded in the platelet-rich fibrin scaffold instead of directly 

AD-CMGs, ADSC-derived cardiomyogenic cells; ADSCs, adipose-derived stem cells; AMI, acute myocardial infarction; Ang-1, angiopoietin-1; b-FGF, basic fibroblast growth factor; BM-MNCs, bone marrow-derived mononuclear cells; BM-MSCs, bone marrow-derived mesenchymal stem cells; CDCs, cardiosphere-derived cells; eNOS, endothelial nitric oxide synthase; EPCs, endothelial progenitor cells; GFP, green fluorescent protein; HGF, hepatic growth factor; HO-1-ADSCs, adipose-derived stem cells transduced with heme oxygenase-1; IGF-1, insulin-like growth factor 1; LAD, left anterior descending coronary artery; LVEF, left ventricular ejection fraction; MSCs, mesenchymal stem cells; SCID, severe combined immunodeficiency; SD, Sprague Dawley; shPHD2, prolyl hydroxylase domain protein 2; SNAP, S-Nitroso-N-acetyl-DL-penicillamine; SVF, stromal vascular fraction; TGFβ-1, transforming growth factor β1; VEGF, vascular endothelial growth factor.

Table 4.

Preclinical Studies with Porcine Models

Authors  Cell source  Animal model  Lesion  Result 
Watanabe et al96  ADSCs  Pig  AMI induced by LAD occlusion  After 6 months, LVEF increased by 3% 
Fotuhi et al97  ADSCs from pig subcutaneous adipose tissue  Pig  AMI induced by LAD ligation  Decreased arrhythmogenesis 
Valina et al93  Pig ADSCs from subcutaneous adipose tissue or BM-MSCs  Pig  AMI induced by LAD angioplasty  After 4 weeks, improved LVEF, capillary density, and thickening of the heart wall 
Alt et al94  ADSCs from pig subcutaneous adipose tissue  Pig  AMI induced by LAD occlusion and reperfusion  Better perfusion, LVEF, capillary density, and myocardial recovery 
Rigol et al92  ADSCs from pig subcutaneous adipose tissue via intracoronary and transendocardial administration  Pig  AMI  Increased number of small vessels. Ejection fraction unchanged 
Mazo et al95  Pig ADSCs  Minipigs  Ischemia and reperfusion  After 3 months, improved cardiac function, increased angiogenesis and vasculogenesis, and decreased fibrosis and cardiac hypertrophy 
Yang et al101  Human ADSCs immobilized in agarose gel patches  Pig  AMI induced by cryolesion  After 4 weeks, improved perfusion, reduced infarct zone size, and increased cardiac kinetics 
Song et al98  MSCs, atorvastatin, and NG-nitrol-L-arginine  Minipigs  LAD ligation and reperfusion  After 4 weeks, atorvastatin + MSCs increased LVEF and decreased the inflammation, fibrosis, and apoptosis indices. There was no improvement in cardiac function with atorvastatin or MSCs alone. NG-nitrol-L-arginine partially blocked the improvements seen 
Yin et al99  CMTA + CsA-NP  Minipigs  AMI induced by LAD occlusion  CsA-NP increased ADSC viability and improved LVEF 
Rigol et al100  ADSCs  Pig  AMI  ADSCs administration immediately after reperfusion is more effective and improves neovascularization 

ADSCs, adipose-derived stem cells; AMI, acute myocardial infarction; BM-MSCs, bone marrow-derived mesenchymal stem cells; CsA-NP, cyclosporine A-nanoparticle emulsion; LAD, left anterior descending coronary artery; LVEF, left ventricular ejection fraction; MSCs, mesenchymal stem cells.

Another important function of ADSCs related to ischemic heart disease is derived from their angiogenic potential.52,109 Because ADSCs secrete a large number of proangiogenic cytokines and cytoprotective factors, they are an ideal cellular source for angiogenic therapy and apoptosis inhibition.29,110–112 An in vivo study showed that intramyocardial injection of human ADSCs significantly promoted angiogenesis and inhibited cell apoptosis in an infarcted heart 4 weeks after their injection.54 Moreover, ADSCs showed an increased expression of vascular endothelial and fibroblast growth factors and stromal cell-derived factor 1.54 Indeed, the interaction of stromal cell-derived factor 1 with its receptor induces the rapid mobilization of stem/progenitor cells from the bone marrow,113 which is essential for the revascularization of body systems.114 All of these results indicate that injected ADSCs cooperate with stem/progenitor cells of the bone marrow via cellular mobilization, which is promoted by stromal cell-derived factor 1 and which boosts angiogenesis and vasculogenesis in myocardial ischemia.54

The functional response of ADSCs can also be affected by oxygen concentration.29,115 Rehman et al29 found that ADSCs secreted up to 5 times more vascular endothelial growth factors if they were cultured under hypoxic conditions. Additionally, the conditioned supernatant of ADSCs cultured under hypoxic conditions increased the growth of endothelial cells and reduced their apoptosis. Recently, a study reported that hypoxic preconditioning of ADSCs increased their survival and paracrine effects in a hypoxia-inducible factor 1-mediated manner.116 Indeed, our laboratory group has shown that ADSCs cultured under hypoxic conditions had greatly improved proliferative capacity.40 These results showed that ADSCs respond to ischemic situations and promote angiogenesis via the secretion of vascular endothelial growth factors. As already mentioned, various experimental studies have shown that ADSCs are safe and efficacious (Tables 3 and 4). As can be seen in Table 4, 2 studies showed an increased capillary density in the area surrounding the infarcted heart and an increased cardiac function 1 month after a myocardial infarction when animals were treated with ADSCs, results similar to those observed after bone marrow-derived MSCs administration.93,94 A long-term follow-up study showed that, despite an inability to detect ADSCs in the myocardium 3 months after their injection, ADSC transplantation was associated with increased cardiac function, positive remodeling, and increased angiogenesis and vasculogenesis, confirming the long-term paracrine effect of these cells.95 However, these observations indicate that, despite all of the advantages of ADSCs, their low capacity for homing to ischemic tissue is an obstacle to their clinical use.117 Accordingly, various strategies are being explored to resolve the problem of ADSC survival and engraftment in host tissue, such as the administration of ADSCs together with a combination of growth factors,118 injection of genetically modified ADSCs,119 and/or the use of grafts/biomaterial scaffolds.120,121 Finally, it is necessary to mention that various studies have indicated that ADSCs, both in vitro and in vivo, can boost the differentiation of the vasculature into pericytes, cells capable of creating microvessels, preventing vascular regression, and promoting long-term microvessel maintenance.122,123

Clinical Trials

The evidence found in the experimental studies of the potential of ADSCs to repair the ischemic myocardium and restore its functional capacity has prompted the performance of clinical trials in this area. However, although some researchers believe that ADSCs will be used in the coming years as a cell therapy aimed at repairing the damaged heart, others believe that there are many unknowns to be resolved before these cells can be clinically used. So far, ADSCs have been satisfactorily used to treat some diseases, such as Crohn's fistula, osteogenesis imperfecta, and breast reconstruction after a partial mastectomy (Table 5). However, the use of ADSCs in the field of ischemic heart disease is still in phase I-II. Various clinical trials have been initiated to determine the feasibility, safety, and efficacy of the use of ADSCs in patients who have had an acute myocardial infarction (APOLLO, ADI-ME-CHF-002, ADVANCE, and ACUTE MI), have chronic ischemic heart disease (PRECISE, MyStromalCell, ATHENA, and ATHENA II), or nonischemic cardiomyopathy (ADI-ME-CHF-002). Of these, the APOLLO124, PRECISE,125 and MyStromalCell126 trials have been completed. These studies showed that the use of ADSCs is safe and feasible. In addition, the results indicated that ADSC use preserves cardiac function, improves cardiac perfusion, and even reduces scar tissue size, thereby reinforcing the findings of the previous preclinical trials.

Table 5.

Clinical Trials Performed with Adipose-derived Stem Cells

Disorder  Studies, no. 
Metabolic disease
Lipodystrophy 
Diabetes mellitus 
Cardiovascular disease
Vascular disease 
Ischemic heart disease  11 
Stroke 
Rheumatic disorders
Tendon injury 
Arthritis 
Degenerative disc disease 
Necrosis 
Renal and urological disorders
Urinary incontinence 
Renal failure 
Urethral disorders 
Endocrine system diseases 
Respiratory disorders 
Nervous system diseases
Ataxia 
Facial hemiatrophy 
Multiple sclerosis 
Parkinson disease 
Spinal cord disorders 
Brain damage 
Mental disorders 
Digestive system diseases
Intestinal disorders 
Cirrhosis 
Fibrosis  11 
Breast diseases 
Graft-versus-host disease 
Crohn disease 
Autologous fat grafting 
Frailty syndrome 
FUTURE PROSPECTS

Thus, ADSCs are appearing as a viable cell therapy alternative in various medical fields, which will require a better understanding of the mechanisms used by these cells or their paracrine factors in tissue regeneration/recovery, as well as the key molecular factors promoting the differentiation of ADSCs to different lineages. Additionally, it remains to be determined whether therapeutic efficacy is affected by the anatomical source of the cells, the sex and age of the donor, or the presence of comorbidities. The possibility of using both autologous and allogeneic ADSCs should also be considered, because various independent studies have reported that ADSCs have a low immunostimulatory potential.127,128

FUNDING

Part of the work contained in this manuscript was financed by the Programa Nacional de Salud (SAF 2013-42962-R, awarded to L. Badimon; SAF 2012-40208 awarded to G. Vilahur), the Instituto de Salud Carlos III (TerCel [Red de Terapia Celular] RD12/0019/0026), and the Fundación Jesús Serra (FIC-Barcelona).

CONFLICTS OF INTEREST

None declared.

Acknowledgments

We thank the Fundación Jesús Serra of Barcelona for its continuing support. G. Vilahur is a Ramón y Cajal researcher with a contract with the Secretaría de Estado de Investigación, Desarrollo e Innovación from the Ministerio de Economía y Competitividad of Spain (RyC-2009-5495).

References
[1]
E.E. Kershaw, J.S. Flier.
Adipose tissue as an endocrine organ.
J Clin Endocrinol Metab., 89 (2004), pp. 2548-2556
[2]
A. Gil, J. Olza, M. Gil-Campos, C. Gomez-Llorente, C.M. Aguilera.
Is adipose tissue metabolically different at different sites?.
Int J Pediatr Obes., 6 (2011), pp. 13-20
[3]
A. Villaret, J. Galitzky, P. Decaunes, D. Esteve, M.A. Marques, C. Sengenes, et al.
Adipose tissue endothelial cells from obese human subjects: differences among depots in angiogenic, metabolic, and inflammatory gene expression and cellular senescence.
Diabetes., 59 (2010), pp. 2755-2763
[4]
M.M. Ibrahim.
Subcutaneous and visceral adipose tissue: structural and functional differences.
[5]
C.J. Dobbelsteyn, M.R. Joffres, D.R. MacLean, G. Flowerdew.
A comparative evaluation of waist circumference, waist-to-hip ratio and body mass index as indicators of cardiovascular risk factors. The Canadian Heart Health Surveys.
Int J Obes Relat Metab Disord., 25 (2001), pp. 652-661
[6]
H. Kanai, Y. Matsuzawa, K. Kotani, Y. Keno, T. Kobatake, Y. Nagai, et al.
Close correlation of intra-abdominal fat accumulation to hypertension in obese women.
Hypertension., 16 (1990), pp. 484-490
[7]
O.T. Ayonrinde, J.K. Olynyk, L.J. Beilin, T.A. Mori, C.E. Pennell, N. De Klerk, et al.
Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease.
Hepatology., 53 (2011), pp. 800-809
[8]
A. Wronska, Z. Kmiec.
Structural and biochemical characteristics of various white adipose tissue depots.
Acta Physiol (Oxf)., 205 (2012), pp. 194-208
[9]
K. Jaworski, E. Sarkadi-Nagy, R.E. Duncan, M. Ahmadian, H.S. Sul.
Regulation of triglyceride metabolism. IV. Hormonal regulation of lipolysis in adipose tissue.
Am J Physiol Gastrointest Liver Physiol., 293 (2007), pp. G1-G4
[10]
E. Duplus, M. Glorian, C. Forest.
Fatty acid regulation of gene transcription.
J Biol Chem., 275 (2000), pp. 30749-30752
[11]
M.T. Sheehan, M.D. Jensen.
Metabolic complications of obesity. Pathophysiologic considerations.
Med Clin North Am., 84 (2000), pp. 363-385
[12]
P.R. Shepherd, L. Gnudi, E. Tozzo, H. Yang, F. Leach, B.B. Kahn.
Adipose cell hyperplasia and enhanced glucose disposal in transgenic mice overexpressing GLUT4 selectively in adipose tissue.
J Biol Chem., 268 (1993), pp. 22243-22246
[13]
J.M. Gimble, A.J. Katz, B.A. Bunnell.
Adipose-derived stem cells for regenerative medicine.
Circ Res., 100 (2007), pp. 1249-1260
[14]
J.M. Rutkowski, K.E. Davis, P.E. Scherer.
Mechanisms of obesity and related pathologies: the macro- and microcirculation of adipose tissue.
FEBS J., 276 (2009), pp. 5738-5746
[15]
H.S. Schipper, B. Prakken, E. Kalkhoven, M. Boes.
Adipose tissue-resident immune cells: key players in immunometabolism.
Trends Endocrinol Metab., 23 (2012), pp. 407-415
[16]
S.P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R.L. Leibel, A.W. Ferrante Jr..
Obesity is associated with macrophage accumulation in adipose tissue.
J Clin Invest., 112 (2003), pp. 1796-1808
[17]
C.N. Lumeng, J.L. Bodzin, A.R. Saltiel.
Obesity induces a phenotypic switch in adipose tissue macrophage polarization.
J Clin Invest., 117 (2007), pp. 175-184
[18]
W.P. Cawthorn, E.L. Scheller, O.A. MacDougald.
Adipose tissue stem cells meet preadipocyte commitment: going back to the future.
J Lipid Res., 53 (2012), pp. 227-246
[19]
S. Kim, N. Moustaid-Moussa.
Secretory, endocrine and autocrine/paracrine function of the adipocyte.
J Nutr., 130 (2000), pp. S3110-S3115
[20]
T. Ronti, G. Lupattelli, E. Mannarino.
The endocrine function of adipose tissue: an update.
Clin Endocrinol (Oxf)., 64 (2006), pp. 355-365
[21]
M. Tesauro, M.P. Canale, G. Rodia, N. Di Daniele, D. Lauro, A. Scuteri, et al.
Metabolic syndrome, chronic kidney, and cardiovascular diseases: role of adipokines.
Cardiol Res Pract., (2011), pp. 653182
[22]
P.A. Zuk, M. Zhu, H. Mizuno, J. Huang, J.W. Futrell, A.J. Katz, et al.
Multilineage cells from human adipose tissue: implications for cell-based therapies.
Tissue Engineering., 7 (2001), pp. 211-228
[23]
S. Gesta, Y.H. Tseng, C.R. Kahn.
Developmental origin of fat: tracking obesity to its source.
Cell., 131 (2007), pp. 242-256
[24]
D.A. De Ugarte, K. Morizono, A. Elbarbary, Z. Alfonso, P.A. Zuk, M. Zhu, et al.
Comparison of multi-lineage cells from human adipose tissue and bone marrow.
Cells Tissues Organs., 174 (2003), pp. 101-109
[25]
E. Mansilla, V. Díaz Aquino, D. Zambón, G.H. Marin, K. Mártire, G. Roque, et al.
Could metabolic syndrome, lipodystrophy, and aging be mesenchymal stem cell exhaustion syndromes?.
Stem Cells Int., (2011), pp. 943216
[26]
M.G. Kolonin, K.W. Evans, S.A. Mani, R.H. Gomer.
Alternative origins of stroma in normal organs and disease.
Stem Cell Res., 8 (2012), pp. 312-323
[27]
M. Dominici, K. Le Blanc, I. Mueller, I. Slaper-Cortenbach, F. Marini, D. Krause, et al.
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.
Cytotherapy., 8 (2006), pp. 315-317
[28]
A.J. Salgado, R.L. Reis, N.J. Sousa, J.M. Gimble.
Adipose tissue derived stem cells secretome: soluble factors and their roles in regenerative medicine.
Curr Stem Cell Res Ther., 5 (2010), pp. 103-110
[29]
J. Rehman, D. Traktuev, J. Li, S. Merfeld-Clauss, C.J. Temm-Grove, J.E. Bovenkerk, et al.
Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells.
Circulation., 109 (2004), pp. 1292-1298
[30]
S. Perrini, L. Laviola, A. Cignarelli, M. Melchiorre, F. De Stefano, C. Caccioppoli, et al.
Fat depot-related differences in gene expression, adiponectin secretion, and insulin action and signalling in human adipocytes differentiated in vitro from precursor stromal cells.
Diabetologia., 51 (2008), pp. 155-164
[31]
T. Tchkonia, N. Giorgadze, T. Pirtskhalava, T. Thomou, M. DePonte, A. Koo, et al.
Fat depot-specific characteristics are retained in strains derived from single human preadipocytes.
Diabetes., 55 (2006), pp. 2571-2578
[32]
V. Van Harmelen, K. Rohrig, H. Hauner.
Comparison of proliferation and differentiation capacity of human adipocyte precursor cells from the omental and subcutaneous adipose tissue depot of obese subjects.
Metabolism., 53 (2004), pp. 632-637
[33]
T. Tchkonia, M. Lenburg, T. Thomou, N. Giorgadze, G. Frampton, T. Pirtskhalava, et al.
Identification of depot-specific human fat cell progenitors through distinct expression profiles and developmental gene patterns.
Am J Physiol Endocrinol Metab., 292 (2007), pp. E298-E307
[34]
S. Gesta, M. Bluher, Y. Yamamoto, A.W. Norris, J. Berndt, S. Kralisch, et al.
Evidence for a role of developmental genes in the origin of obesity and body fat distribution.
Proc Natl Acad Sci U S A., 103 (2006), pp. 6676-6681
[35]
S.M. Majka, Y. Barak, D.J. Klemm.
Concise review: adipocyte origins: weighing the possibilities.
Stem Cells., 29 (2011), pp. 1034-1040
[36]
J. Hoffstedt, E. Arner, H. Wahrenberg, D.P. Andersson, V. Qvisth, P. Lofgren, et al.
Regional impact of adipose tissue morphology on the metabolic profile in morbid obesity.
Diabetologia., 53 (2010), pp. 2496-2503
[37]
R. Ferrer-Lorente, M.T. Bejar, M. Tous, G. Vilahur, L. Badimon.
Systems biology approach to identify alterations in the stem cell reservoir of subcutaneous adipose tissue in a rat model of diabetes: effects on differentiation potential and function.
Diabetologia., 57 (2014), pp. 246-256
[38]
V. Van Harmelen, T. Skurk, K. Rohrig, Y.M. Lee, M. Halbleib, I. Aprath-Husmann, et al.
Effect of BMI and age on adipose tissue cellularity and differentiation capacity in women.
Int J Obes Relat Metab Disord., 27 (2003), pp. 889-895
[39]
S. Nair, Y.H. Lee, E. Rousseau, M. Cam, P.A. Tataranni, L.J. Baier, et al.
Increased expression of inflammation-related genes in cultured preadipocytes/stromal vascular cells from obese compared with non-obese Pima Indians.
Diabetologia., 48 (2005), pp. 1784-1788
[40]
B. Oñate, G. Vilahur, R. Ferrer-Lorente, J. Ybarra, A. Díez-Caballero, C. Ballesta-López, et al.
The subcutaneous adipose tissue reservoir of functionally active stem cells is reduced in obese patients.
FASEB J., 26 (2012), pp. 4327-4336
[41]
B. Oñate, G. Vilahur, S. Camino-López, A. Díez-Caballero, C. Ballesta-López, J. Ybarra, et al.
Stem cells isolated from adipose tissue of obese patients show changes in their transcriptomic profile that indicate loss in stemcellness and increased commitment to an adipocyte-like phenotype.
BMC Genomics., 14 (2013), pp. 625
[42]
M. Roldan, M. Macias-Gonzalez, R. Garcia, F.J. Tinahones, M. Martin.
Obesity short-circuits stemness gene network in human adipose multipotent stem cells.
FASEB J., 25 (2011), pp. 4111-4126
[43]
N. Smart, P.R. Riley.
The stem cell movement.
Circ Res., 102 (2008), pp. 1155-1168
[44]
J.M. Gimble, B.A. Bunnell, F. Guilak.
Human adipose-derived cells: an update on the transition to clinical translation.
Regen Med., 7 (2012), pp. 225-235
[45]
H. Mizuno, M. Tobita, A.C. Uysal.
Concise review: Adipose-derived stem cells as a novel tool for future regenerative medicine.
Stem Cells., 30 (2012), pp. 804-810
[46]
A. Miranville, C. Heeschen, C. Sengenès, C.A. Curat, R. Busse, A. Bouloumié.
Improvement of postnatal neovascularization by human adipose tissue-derived stem cells.
Circulation., 110 (2004), pp. 349-355
[47]
S. Makino, K. Fukuda, S. Miyoshi, F. Konishi, H. Kodama, J. Pan, et al.
Cardiomyocytes can be generated from marrow stromal cells in vitro.
J Clin Invest., 103 (1999), pp. 697-705
[48]
D.J. Prockop.
Marrow stromal cells as stem cells for nonhematopoietic tissues.
Science., 276 (1997), pp. 71-74
[49]
M.F. Pittenger, A.M. Mackay, S.C. Beck, R.K. Jaiswal, R. Douglas, J.D. Mosca, et al.
Multilineage potential of adult human mesenchymal stem cells.
Science., 284 (1999), pp. 143-147
[50]
N. Nagaya, T. Fujii, T. Iwase, H. Ohgushi, T. Itoh, M. Uematsu, et al.
Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis.
Am J Physiol Heart Circ Physiol., 287 (2004), pp. H2670-H2676
[51]
B.M. Strem, M. Zhu, Z. Alfonso, E.J. Daniels, R. Schreiber, R. Beygui, et al.
Expression of cardiomyocytic markers on adipose tissue-derived cells in a murine model of acute myocardial injury.
Cytotherapy., 7 (2005), pp. 282-291
[52]
L. Cai, B.H. Johnstone, T.G. Cook, J. Tan, M.C. Fishbein, P.S. Chen, et al.
IFATS collection: Human adipose tissue-derived stem cells induce angiogenesis and nerve sprouting following myocardial infarction, in conjunction with potent preservation of cardiac function.
Stem Cells., 27 (2009), pp. 230-237
[53]
X. Bai, Y. Yan, Y.H. Song, M. Seidensticker, B. Rabinovich, R. Metzele, et al.
Both cultured and freshly isolated adipose tissue-derived stem cells enhance cardiac function after acute myocardial infarction.
Eur Heart J., 31 (2010), pp. 489-501
[54]
M. Ii, M. Horii, A. Yokoyama, T. Shoji, Y. Mifune, A. Kawamoto, et al.
Synergistic effect of adipose-derived stem cell therapy and bone marrow progenitor recruitment in ischemic heart.
Lab Invest., 91 (2011), pp. 539-552
[55]
Y. Miyahara, N. Nagaya, M. Kataoka, B. Yanagawa, K. Tanaka, H. Hao, et al.
Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction.
Nat Med., 12 (2006), pp. 459-465
[56]
D.Z. Zhang, L.Y. Gai, H.W. Liu, Q.H. Jin, J.H. Huang, X.Y. Zhu.
Transplantation of autologous adipose-derived stem cells ameliorates cardiac function in rabbits with myocardial infarction.
Chin Med J (Engl)., 120 (2007), pp. 300-307
[57]
M. Mazo, V. Planat-Bénard, G. Abizanda, B. Pelacho, B. Léobon, J.J. Gavira, et al.
Transplantation of adipose derived stromal cells is associated with functional improvement in a rat model of chronic myocardial infarction.
Eur J Heart Fail., 10 (2008), pp. 454-462
[58]
B. Léobon, J. Roncalli, C. Joffre, M. Mazo, M. Boisson, C. Barreau, et al.
Adipose-derived cardiomyogenic cells: in vitro expansion and functional improvement in a mouse model of myocardial infarction.
Cardiovasc Res., 83 (2009), pp. 757-767
[59]
K. Schenke-Layland, B.M. Strem, M.C. Jordan, M.T. Deemedio, M.H. Hedrick, K.P. Roos, et al.
Adipose tissue-derived cells improve cardiac function following myocardial infarction.
J Surg Res., 153 (2009), pp. 217-223
[60]
K.E. Van der Bogt, S. Schrepfer, J. Yu, A.Y. Sheikh, G. Hoyt, J.A. Govaert, et al.
Comparison of transplantation of adipose tissue- and bone marrow-derived mesenchymal stem cells in the infarcted heart.
Transplantation., 87 (2009), pp. 642-652
[61]
L. Wang, J. Deng, W. Tian, B. Xiang, T. Yang, G. Li, et al.
Adipose-derived stem cells are an effective cell candidate for treatment of heart failure: an MR imaging study of rat hearts.
Am J Physiol Heart Circ Physiol., 297 (2009), pp. H1020-H1031
[62]
X.Y. Zhu, X.Z. Zhang, L. Xu, X.Y. Zhong, Q. Ding, Y.X. Chen.
Transplantation of adipose-derived stem cells overexpressing hHGF into cardiac tissue.
Biochem Biophys Res Commun., 379 (2009), pp. 1084-1090
[63]
A. Bayes-Genis, C. Soler-Botija, J. Farré, P. Sepulveda, A. Raya, S. Roura, et al.
Human progenitor cells derived from cardiac adipose tissue ameliorate myocardial infarction in rodents.
J Mol Cell Cardiol., 49 (2010), pp. 771-780
[64]
M.E. Danoviz, J.S. Nakamuta, F.L. Marques, L. Dos Santos, E.C. Alvarenga, A.A. Dos Santos, et al.
Rat adipose tissue-derived stem cells transplantation attenuates cardiac dysfunction post infarction and biopolymers enhance cell retention.
[65]
S. Hwangbo, J. Kim, S. Her, H. Cho, J. Lee.
Therapeutic potential of human adipose stem cells in a rat myocardial infarction model.
Yonsei Med J., 51 (2010), pp. 69-76
[66]
Y.C. Lin, S. Leu, C.K. Sun, C.H. Yen, Y.H. Kao, L.T. Chang, et al.
Early combined treatment with sildenafil and adipose-derived mesenchymal stem cells preserves heart function in rat dilated cardiomyopathy.
J Transl Med., 8 (2010), pp. 88
[67]
H. Okura, A. Matsuyama, C.M. Lee, A. Saga, A. Kakuta-Yamamoto, A. Nagao, et al.
Cardiomyoblast-like cells differentiated from human adipose tissue-derived mesenchymal stem cells improve left ventricular dysfunction and survival in a rat myocardial infarction model.
Tissue Eng Part C Methods., 16 (2010), pp. 417-425
[68]
X. Zhang, H. Wang, X. Ma, A. Adila, B. Wang, F. Liu, et al.
Preservation of the cardiac function in infarcted rat hearts by the transplantation of adipose-derived stem cells with injectable fibrin scaffolds.
Exp Biol Med (Maywood)., 235 (2010), pp. 1505-1515
[69]
X. Bai, Y. Yan, M. Coleman, G. Wu, B. Rabinovich, M. Seidensticker, et al.
Tracking long-term survival of intramyocardially delivered human adipose tissue-derived stem cells using bioluminescence imaging.
Mol Imaging Biol., 13 (2011), pp. 633-645
[70]
G.R. Berardi, C.K. Rebelatto, H.F. Tavares, M. Ingberman, P. Shigunov, F. Barchiki, et al.
Transplantation of SNAP-treated adipose tissue-derived stem cells improves cardiac function and induces neovascularization after myocardium infarct in rats.
Exp Mol Pathol., 90 (2011), pp. 149-156
[71]
A. Cai, D. Zheng, Y. Dong, R. Qiu, Y. Huang, Y. Song, et al.
Efficacy of atorvastatin combined with adipose-derived mesenchymal stem cell transplantation on cardiac function in rats with acute myocardial infarction.
Acta Biochim Biophys Sin (Shanghai)., 43 (2011), pp. 857-866
[72]
R. Gaebel, D. Furlani, H. Sorg, B. Polchow, J. Frank, K. Bieback, et al.
Cell origin of human mesenchymal stem cells determines a different healing performance in cardiac regeneration.
[73]
H. Hamdi, V. Planat-Benard, A. Bel, E. Puymirat, R. Geha, L. Pidial, et al.
Epicardial adipose stem cell sheets results in greater post-infarction survival than intramyocardial injections.
Cardiovasc Res., 91 (2011), pp. 483-491
[74]
A. Van Dijk, B.A. Naaijkens, W.J. Jurgens, K. Nalliah, S. Sairras, R.J. Van der Pijl, et al.
Reduction of infarct size by intravenous injection of uncultured adipose derived stromal cells in a rat model is dependent on the time point of application.
Stem Cell Res., 7 (2011), pp. 219-229
[75]
L.L. Bagno, J.P. Werneck-de-Castro, P.F. Oliveira, M.S. Cunha-Abreu, N.N. Rocha, T.H. Kasai-Brunswick, et al.
Adipose-derived stromal cell therapy improves cardiac function after coronary occlusion in rats.
Cell Transplant., 21 (2012), pp. 1985-1996
[76]
J.O. Beitnes, E. Oie, A. Shahdadfar, T. Karlsen, R.M. Muller, S. Aakhus, et al.
Intramyocardial injections of human mesenchymal stem cells following acute myocardial infarction modulate scar formation and improve left ventricular function.
Cell Transplant., 21 (2012), pp. 1697-1709
[77]
C.H. Fang, J. Jin, J.H. Joe, Y.S. Song, B.I. So, S.M. Lim, et al.
In vivo differentiation of human amniotic epithelial cells into cardiomyocyte-like cells and cell transplantation effect on myocardial infarction in rats: comparison with cord blood and adipose tissue-derived mesenchymal stem cells.
Cell Transplant., 21 (2012), pp. 1687-1696
[78]
N.N. Hoke, F.N. Salloum, D.A. Kass, A. Das, R.C. Kukreja.
Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice.
Stem Cells., 30 (2012), pp. 326-335
[79]
T.S. Li, K. Cheng, K. Malliaras, R.R. Smith, Y. Zhang, B. Sun, et al.
Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells.
J Am Coll Cardiol., 59 (2012), pp. 942-953
[80]
Z. Liu, H. Wang, Y. Wang, Q. Lin, A. Yao, F. Cao, et al.
The influence of chitosan hydrogel on stem cell engraftment, survival and homing in the ischemic myocardial microenvironment.
Biomaterials., 33 (2012), pp. 3093-3106
[81]
A. Paul, G. Chen, A. Khan, V.T. Rao, D. Shum-Tim, S. Prakash.
Genipin-cross-linked microencapsulated human adipose stem cells augment transplant retention resulting in attenuation of chronically infarcted rat heart fibrosis and cardiac dysfunction.
Cell Transplant., 21 (2012), pp. 2735-2751
[82]
A. Paul, M. Nayan, A.A. Khan, D. Shum-Tim, S. Prakash.
Angiopoietin-1-expressing adipose stem cells genetically modified with baculovirus nanocomplex: investigation in rat heart with acute infarction.
Int J Nanomedicine., 7 (2012), pp. 663-682
[83]
C.Z. Shi, X.P. Zhang, Z.W. Lv, H.L. Zhang, J.Z. Xu, Z.F. Yin, et al.
Adipose tissue-derived stem cells embedded with eNOS restore cardiac function in acute myocardial infarction model.
Int J Cardiol., 154 (2012), pp. 2-8
[84]
J.J. Yang, X. Yang, Z.Q. Liu, S.Y. Hu, Z.Y. Du, L.L. Feng, et al.
Transplantation of adipose tissue-derived stem cells overexpressing heme oxygenase-1 improves functions and remodeling of infarcted myocardium in rabbits.
Tohoku J Exp Med., 226 (2012), pp. 231-241
[85]
A. Paul, S. Srivastava, G. Chen, D. Shum-Tim, S. Prakash.
Functional assessment of adipose stem cells for xenotransplantation using myocardial infarction immunocompetent models: comparison with bone marrow stem cells.
Cell Biochem Biophys., 67 (2013), pp. 263-273
[86]
W.E. Wang, D. Yang, L. Li, W. Wang, Y. Peng, C. Chen, et al.
Prolyl hydroxylase domain protein 2 silencing enhances the survival and paracrine function of transplanted adipose-derived stem cells in infarcted myocardium.
Circ Res., 113 (2013), pp. 288-300
[87]
A.F. Godier-Furnémont, Y. Tekabe, M. Kollaros, G. Eng, A. Morales, G. Vunjak-Novakovic, et al.
Noninvasive imaging of myocyte apoptosis following application of a stem cell-engineered delivery platform to acutely infarcted myocardium.
J Nucl Med., 54 (2013), pp. 977-983
[88]
A.A. Karpov, Y.K. Uspenskaya, S.M. Minasian, M.V. Puzanov, R.I. Dmitrieva, A.A. Bilibina, et al.
The effect of bone marrow- and adipose tissue-derived mesenchymal stem cell transplantation on myocardial remodelling in the rat model of ischaemic heart failure.
Int J Exp Pathol., 94 (2013), pp. 169-177
[89]
Q. Jiang, P. Song, E. Wang, J. Li, S. Hu, H. Zhang.
Remote ischemic postconditioning enhances cell retention in the myocardium after intravenous administration of bone marrow mesenchymal stromal cells.
J Mol Cell Cardiol., 56 (2013), pp. 1-7
[90]
S.J. Hong, J. Kihlken, S.C. Choi, K.L. March, D.S. Lim.
Intramyocardial transplantation of human adipose-derived stromal cell and endothelial progenitor cell mixture was not superior to individual cell type transplantation in improving left ventricular function in rats with myocardial infarction.
Int J Cardiol., 164 (2013), pp. 205-211
[91]
C.K. Sun, Y.Y. Zhen, S. Leu, T.H. Tsai, L.T. Chang, J.J. Sheu, et al.
Direct implantation versus platelet-rich fibrin-embedded adipose-derived mesenchymal stem cells in treating rat acute myocardial infarction.
Int J Cardiol., 173 (2014), pp. 410-423
[92]
M. Rigol, N. Solanes, J. Farré, S. Roura, M. Roqué, A. Berruezo, et al.
Effects of adipose tissue-derived stem cell therapy after myocardial infarction: impact of the route of administration.
J Card Fail., 16 (2010), pp. 357-366
[93]
C. Valina, K. Pinkernell, Y.H. Song, X. Bai, S. Sadat, R.J. Campeau, et al.
Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction.
Eur Heart J., 28 (2007), pp. 2667-2677
[94]
E. Alt, K. Pinkernell, M. Scharlau, M. Coleman, P. Fotuhi, C. Nabzdyk, et al.
Effect of freshly isolated autologous tissue resident stromal cells on cardiac function and perfusion following acute myocardial infarction.
Int J Cardiol., 144 (2010), pp. 26-35
[95]
M. Mazo, S. Hernández, J.J. Gavira, G. Abizanda, M. Arana, T. López-Martínez, et al.
Treatment of reperfused ischemia with adipose-derived stem cells in a preclinical Swine model of myocardial infarction.
Cell Transplant., 21 (2012), pp. 2723-2733
[96]
C. Watanabe.
Intracoronary adipose tissue derived stem cells therapy preserves left ventricular function in a porcine infarct model.
Transvascular Cardiovascular Therapeutics Annual Meeting. Washington, September,
[97]
P. Fotuhi, Y.H. Song, E. Alt.
Electrophysiological consequence of adipose-derived stem cell transplantation in infarcted porcine myocardium.
Europace., 9 (2007), pp. 1218-1221
[98]
L. Song, Y.J. Yang, Q.T. Dong, H.Y. Qian, R.L. Gao, S.B. Qiao, et al.
Atorvastatin enhance efficacy of mesenchymal stem cells treatment for swine myocardial infarction via activation of nitric oxide synthase.
[99]
Q.X. Yin, H. Wang, Z.Y. Pei, Y.S. Zhao.
[Efficacy of cyclosporine A-nanoparticles emulsion combined with stem cell transplantation therapy for acute myocardial infarction].
Zhongguo Yi Xue Ke Xue Yuan Xue Bao., 35 (2013), pp. 404-410
[100]
M. Rigol, N. Solanes, S. Roura, M. Roqué, L. Novensà, A.P. Dantas, et al.
Allogeneic adipose stem cell therapy in acute myocardial infarction.
Eur J Clin Invest., 44 (2014), pp. 83-92
[101]
Y. Yang, P. Dreessen de Gervai, J. Sun, M. Glogowski, E. Gussakovsky, V. Kupriyanov.
MRI studies of cryoinjury infarction in pig hearts: ii. Effects of intrapericardial delivery of adipose-derived stem cells (ADSC) embedded in agarose gel.
NMR Biomed., 25 (2012), pp. 227-235
[102]
X. Bai, E. Alt.
Myocardial regeneration potential of adipose tissue-derived stem cells.
Biochem Biophys Res Commun., 401 (2010), pp. 321-326
[103]
Y.M. Kim, E.S. Jeon, M.R. Kim, S.K. Jho, S.W. Ryu, J.H. Kim.
Angiotensin II-induced differentiation of adipose tissue-derived mesenchymal stem cells to smooth muscle-like cells.
Int J Biochem Cell Biol., 40 (2008), pp. 2482-2491
[104]
L.V. Rodríguez, Z. Alfonso, R. Zhang, J. Leung, B. Wu, L.J. Ignarro.
Clonogenic multipotent stem cells in human adipose tissue differentiate into functional smooth muscle cells.
Proc Natl Acad Sci U S A., 103 (2006), pp. 12167-12172
[105]
H. Ning, G. Liu, G. Lin, R. Yang, T.F. Lue, C.S. Lin.
Fibroblast growth factor 2 promotes endothelial differentiation of adipose tissue-derived stem cells.
[106]
S. Hombach-Klonisch, S. Panigrahi, I. Rashedi, A. Seifert, E. Alberti, P. Pocar, et al.
Adult stem cells and their trans-differentiation potential-perspectives and therapeutic applications.
J Mol Med., 86 (2008), pp. 1301-1314
[107]
K.A. Jackson, S.M. Majka, H. Wang, J. Pocius, C.J. Hartley, M.W. Majesky, et al.
Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells.
J Clin Invest., 107 (2001), pp. 1395-1402
[108]
M.A. Laflamme, D. Myerson, J.E. Saffitz, C.E. Murry.
Evidence for cardiomyocyte repopulation by extracardiac progenitors in transplanted human hearts.
Circ Res., 90 (2002), pp. 634-640
[109]
M. Gnecchi, H. He, O.D. Liang, L.G. Melo, F. Morello, H. Mu, et al.
Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells.
Nat Med., 11 (2005), pp. 367-368
[110]
H. Nakagami, K. Maeda, R. Morishita, S. Iguchi, T. Nishikawa, Y. Takami, et al.
Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells.
Arterioscler Thromb Vasc Biol., 25 (2005), pp. 2542-2547
[111]
M. Wang, P.R. Crisostomo, C. Herring, K.K. Meldrum, D.R. Meldrum.
Human progenitor cells from bone marrow or adipose tissue produce VEGF, HGF, and IGF-I in response to TNF by a p38 MAPK-dependent mechanism.
Am J Physiol Regul Integr Comp Physiol., 291 (2006), pp. R880-R884
[112]
A.A. Kocher, M.D. Schuster, M.J. Szabolcs, S. Takuma, D. Burkhoff, J. Wang, et al.
Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function.
Nat Med., 7 (2001), pp. 430-436
[113]
W.C. Liles, H.E. Broxmeyer, E. Rodger, B. Wood, K. Hubel, S. Cooper, et al.
Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist.
Blood., 102 (2003), pp. 2728-2730
[114]
K. Tachibana, S. Hirota, H. Iizasa, H. Yoshida, K. Kawabata, Y. Kataoka, et al.
The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract.
Nature., 393 (1998), pp. 591-594
[115]
J.G. Rasmussen, O. Frobert, L. Pilgaard, J. Kastrup, U. Simonsen, V. Zachar, et al.
Prolonged hypoxic culture and trypsinization increase the pro-angiogenic potential of human adipose tissue-derived stem cells.
Cytotherapy., 13 (2011), pp. 318-328
[116]
S.L. Stubbs, S.T. Hsiao, H.M. Peshavariya, S.Y. Lim, G.J. Dusting, R.J. Dilley.
Hypoxic preconditioning enhances survival of human adipose-derived stem cells and conditions endothelial cells in vitro.
Stem Cells Dev., 21 (2012), pp. 1887-1896
[117]
E. Tateishi-Yuyama, H. Matsubara, T. Murohara, U. Ikeda, S. Shintani, H. Masaki, et al.
Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial.
Lancet., 360 (2002), pp. 427-435
[118]
S.M. Jay, B.R. Shepherd, J.P. Bertram, J.S. Pober, W.M. Saltzman.
Engineering of multifunctional gels integrating highly efficient growth factor delivery with endothelial cell transplantation.
FASEB J., 22 (2008), pp. 2949-2956
[119]
T. Deuse, C. Peter, P.W. Fedak, T. Doyle, H. Reichenspurner, W.H. Zimmermann, et al.
Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction.
Circulation., 120 (2009), pp. 247-254
[120]
J.R. Fitzpatrick 3rd, J.R. Frederick, R.C. McCormick, D.A. Harris, A.Y. Kim, J.R. Muenzer, et al.
Tissue-engineered pro-angiogenic fibroblast scaffold improves myocardial perfusion and function and limits ventricular remodeling after infarction.
J Thorac Cardiovasc Surg., 140 (2010), pp. 667-676
[121]
S.H. Bhang, S.W. Cho, W.G. La, T.J. Lee, H.S. Yang, A.Y. Sun, et al.
Angiogenesis in ischemic tissue produced by spheroid grafting of human adipose-derived stromal cells.
Biomaterials., 32 (2011), pp. 2734-2747
[122]
P.J. Amos, H. Shang, A.M. Bailey, A. Taylor, A.J. Katz, S.M. Peirce.
IFATS collection: The role of human adipose-derived stromal cells in inflammatory microvascular remodeling and evidence of a perivascular phenotype.
Stem Cells., 26 (2008), pp. 2682-2690
[123]
A.C. Zannettino, S. Paton, A. Arthur, F. Khor, S. Itescu, J.M. Gimble, et al.
Multipotential human adipose-derived stromal stem cells exhibit a perivascular phenotype in vitro and in vivo.
J Cell Physiol., 214 (2008), pp. 413-421
[124]
J.H. Houtgraaf, W.K. Den Dekker, B.M. Van Dalen, T. Springeling, R. De Jong, R.J. Van Geuns, et al.
First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction.
J Am Coll Cardiol., 59 (2012), pp. 539-540
[125]
E.C. Perin, R. Sanz-Ruiz, P.L. Sánchez, J. Lasso, R. Pérez-Cano, J.C. Alonso-Farto, et al.
Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE Trial.
Am Heart J., 168 (2014), pp. 88-95
[126]
A.A. Qayyum, M. Haack-Sørensen, A.B. Mathiasen, E. Jørgensen, A. Ekblond, J. Kastrup.
Adipose-derived mesenchymal stromal cells for chronic myocardial ischemia (MyStromalCell Trial): study design.
Regen Med., 7 (2012), pp. 421-428
[127]
J.A. Kode, S. Mukherjee, M.V. Joglekar, A.A. Hardikar.
Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration.
Cytotherapy., 11 (2009), pp. 377-391
[128]
B. Puissant, C. Barreau, P. Bourin, C. Clavel, J. Corre, C. Bousquet, et al.
Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells.
Br J Haematol., 129 (2005), pp. 118-129
Copyright © 2015. Sociedad Española de Cardiología
Idiomas
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.